Goldman Sachs’s Sophiris Bio, Inc. SPHS Stock Holding History

Goldman Sachs’s Portfolio SPHS Stock Details SPHS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-79,855	Closed	-$161K	–	6328
2018 Q1	$161K	Sell	79,855 -57,476	-42%	-$125K	﹤0.01%	5100
2017 Q4	$312K	Buy	+137,331	New	+$299K	﹤0.01%	5157
2017 Q1	–	Sell	-15,822	Closed	-$44K	–	7283
2016 Q4	$44K	Sell	15,822 -10,659	-40%	-$30.2K	﹤0.01%	6425
2016 Q3	$82K	Buy	+26,481	New	+$99.6K	﹤0.01%	6323
2015 Q3	–	Sell	-27,639	Closed	-$22K	–	7799
2015 Q2	$22K	Buy	+27,639	New	+$23.4K	﹤0.01%	7071

Other funds holding SPHS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BRR OpCo Columbus, Ohio $814M AUM 9.75% 1-Year Est. Return

ACM

Alpha Capital Management Austin, Texas $690M AUM 22.82% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Goldman Sachs's SPHS Position: Q2 2018 in Review

Goldman Sachs sold out of Sophiris Bio, Inc. (SPHS) in Q2 2018, closing a stake of 79,855 shares — an estimated $161K sold.

Goldman Sachs first reported a position in SPHS in Q2 2015 and held it in 5 quarters. The position peaked at $312K in Q4 2017. 30 funds tracked by Wall St. Rank hold SPHS as of Q2 2018.

Goldman Sachs reported no remaining Sophiris Bio, Inc. position as of Q2 2018 after selling out during the quarter.
Goldman Sachs sold 79,855 Sophiris Bio, Inc. shares in Q2 2018, an estimated $161K.
Goldman Sachs first reported a position in Sophiris Bio, Inc. in Q2 2015 and held it in 5 quarters.
Goldman Sachs's Sophiris Bio, Inc. position peaked at $312K in Q4 2017.
30 funds tracked by Wall St. Rank held Sophiris Bio, Inc. as of Q2 2018.

Based on Goldman Sachs's 13F filing for Q2 2018, filed 14 Aug 2018.